Solid Biosciences Inc [SLDB] stock prices are up 9.65% to $11.14 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SLDB shares have gain 14.02% over the last week, with a monthly amount glided 53.66%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 7, March 2024, Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD. In a post published today on Yahoo Finance, Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a non-exclusive worldwide license and collaboration agreement with Armatus Bio for the use of Solid’s proprietary capsid AAV-SLB101 for the development and commercialization of Armatus’ vectorized RNAi candidate to treat Facioscapulohumeral muscular dystrophy (FSHD). The AAV-SLB101 capsid has been shown in preclinical studies to have enhanced biodistribution and improved expression in muscle cells.
From an analyst’s perspective:
Solid Biosciences Inc [NASDAQ: SLDB] stock has seen the most recent analyst activity on December 08, 2023, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $9. Previously, Piper Sandler started tracking the stock with Neutral rating on July 12, 2021, and set its price target to $6. On May 27, 2021, Jefferies initiated with a Buy rating and assigned a price target of $7 on the stock. SVB Leerink upgraded its rating to a Outperform and increased its price target to $15 on March 16, 2021. Barclays initiated its recommendation with a Overweight and recommended $13 as its price target on March 09, 2021. Credit Suisse upgraded its rating to Neutral for this stock on January 08, 2021, and upped its price target to $7. In a note dated July 28, 2020, SVB Leerink downgraded an Mkt Perform rating on this stock.
The stock price of Solid Biosciences Inc [SLDB] has been fluctuating between $1.81 and $10.41 over the past year. Currently, Wall Street analysts expect the stock to reach $120 within the next 12 months. Solid Biosciences Inc [NASDAQ: SLDB] shares were valued at $11.14 at the most recent close of the market. An investor can expect a potential return of 977.2% based on the average SLDB price forecast.
Analyzing the SLDB fundamentals
Gross Profit Margin for this corporation currently stands at 0.64% with Operating Profit Margin at -14.4%, Pretax Profit Margin comes in at -11.22%, and Net Profit Margin reading is -8.54%. To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -0.39 and Total Capital is -0.69. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.19.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.28 points at the first support level, and at 9.41 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.00, and for the 2nd resistance point, it is at 12.85.
Solid Biosciences Inc [SLDB] reported earnings per share of -$1.05 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.19/share, meaning a difference of $0.14 and a surprise factor of 11.80%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$1.25 per share as compared to estimates of -$1.53 per share, a difference of $0.28 representing a surprise of 18.30%.
Ratios To Look Out For
It’s worth pointing out that Solid Biosciences Inc [NASDAQ:SLDB]’s Current Ratio is 9.38. In addition, the Quick Ratio stands at 9.38 and the Cash Ratio stands at 3.1.
Transactions by insiders
Recent insider trading involved Ganot Ilan, Director, that happened on Jan 29 ’24 when 139.0 shares were sold. Director, PERCEPTIVE ADVISORS LLC completed a deal on Jan 11 ’24 to buy 3.41 million shares. Meanwhile, Director RA CAPITAL MANAGEMENT, L.P. bought 0.9 million shares on Jan 11 ’24.
